Evidence map›Paper›PMID 32964545›Full record

ArticleChemistry (Weinheim an der Bergstrasse, Germany)2021

Computational Mapping of Dirhodium(II) Catalysts.

Adam I Green, Christopher P Tinworth, Stuart Warriner, Adam Nelson, Natalie Fey

Abstract read
In one paragraph

Article in Chemistry (Weinheim an der Bergstrasse, Germany), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Article
  3. Digital discovery · 2022
    Article
  4. Computational Mapping of Dirhodium(II) Catalysts.Chemistry (Weinheim an der Bergstrasse, Germany) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Adam I GreenSchool of Chemistry and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS29JT, UK.ORCID http://orcid.org/0000-0002-7397-6579
Christopher P TinworthGlaxoSmithKline Medicines Research Centre, Stevenage, SG12NY, UK.ORCID http://orcid.org/0000-0002-2756-707X
Stuart WarrinerSchool of Chemistry and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS29JT, UK.
Adam NelsonSchool of Chemistry and Astbury Centre for Structural Molecular Biology, University of Leeds, Leeds, LS29JT, UK.ORCID http://orcid.org/0000-0003-3886-363X
Natalie FeySchool of Chemistry, University of Bristol, Cantock's Close, Bristol, BS81TS, UK.ORCID http://orcid.org/0000-0003-0609-475X

Funding

Engineering and Physical Sciences Research Council EP/N025652/1GlaxoSmithKline
6 · The paper itself

Abstract

The chemistry of dirhodium(II) catalysts is highly diverse, and can enable the synthesis of many different molecular classes. A tool to aid in catalyst selection, independent of mechanism and reactivity, would therefore be highly desirable. Here, we describe the development of a database for dirhodium(II) catalysts that is based on the principal component analysis of DFT-calculated parameters capturing their steric and electronic properties. This database maps the relevant catalyst space, and may facilitate exploration of the reactivity landscape for any process catalysed by dirhodium(II) complexes. We have shown that one of the principal components of these catalysts correlates with the outcome (e.g. yield, selectivity) of a transformation used in a molecular discovery project. Furthermore, we envisage that this approach will assist the selection of more effective catalyst screening sets, and, hence, the data-led optimisation of a wide range of rhodium-catalysed transformations.

Indexed as

computational chemistrydata-led predictionhomogeneous catalysisligandsrhodium

Identifiers

PMID32964545
PMCPMC7898874

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.